XML 54 R43.htm IDEA: XBRL DOCUMENT v3.20.2
ACQUISITIONS - Narrative (Details)
$ / shares in Units, shares in Millions
3 Months Ended 4 Months Ended 6 Months Ended 9 Months Ended
May 20, 2020
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Sep. 30, 2020
segment
Sep. 30, 2019
USD ($)
Business Acquisition [Line Items]            
Number of operating segments | segment         1  
Zyla Life Sciences            
Business Acquisition [Line Items]            
Merger exchange ratio 2.5          
Business transaction costs associated with merger   $ 0   $ 6,600,000    
Purchase accounting adjustments, net decrease to goodwill   $ 5,100,000 $ 5,139,000      
Issued (in shares) | shares 5.0          
Proforma information adjustment, excluded income from Zyla's January 2019 Reorganization           $ 115,200,000
Zyla Life Sciences | Iroko | Warrant Agreements            
Business Acquisition [Line Items]            
Exercise aggregate ownership percentage maximum threshold 49.00%          
Exercise aggregate ownership percentage term 18 months          
Zyla Life Sciences | 2019 Plan            
Business Acquisition [Line Items]            
Issued (in shares) | shares 5.0          
Issued, average fair market value, per share (in dollars per share) | $ / shares $ 0.62          
Issued, value recognized as merger consideration $ 400,000          
Zyla Life Sciences | Stock options, awards and equivalents | 2019 Plan            
Business Acquisition [Line Items]            
Merger exchange ratio 2.5          
Vesting period 3 years          
Zyla Life Sciences | Stock options, awards and equivalents | 2019 Plan | Maximum            
Business Acquisition [Line Items]            
Term of award (may not exceed) 10 years          
Zyla Life Sciences | Stock options, awards and equivalents | 2019 Plan | Minimum            
Business Acquisition [Line Items]            
Awards vesting by the end of the first year 33.00%